Clinical trial
An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
NCT06503224 is registered in ClinicalTrials.gov with The First Affiliated Hospital of University of Science and Technology of China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
- Lead sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- April 9, 2024
- Completion date
- April 30, 2028
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.